Bowen disease
Conditions
Interventions
Patients with Bowen's disease will be treated with imiquimod 5% applied to the target site 3 times a week before bedtime. Three courses of 3 weekly applications will be repeated for 4 weeks, followed
Sponsors
Yoshikawa Shusuke
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Histopathologically diagnosed Bowen's disease on biopsy (2) Tumor lesion size of 10 mm or greater on the trunk and extremities, excluding lesions on the head and neck, fingernail area, external genitalia, and perianal area. (3) Obvious neoplastic lesion on pre-registration CT. (4) Over 18 years old (5) Written consent to participate in the study has been obtained from the patient (6) ECOG PS 0-2
Exclusion criteria
Exclusion criteria: (1) Previous topical treatment, cryotherapy, radiation therapy, or post-surgical treatment for Bowen's disease (2) Multiple Bowen lesions (3) Strong inflammatory findings (4) Systemic infection (5) Difficulty in performing topical treatment as prescribed (6) Psychiatric illness or psychiatric symptoms that interfere with daily life (7) On continuous administration of steroids or other immunosuppressive drugs (8) Patients with a history of hypersensitivity to imiquimod (9) Patients who are judged to be inappropriate for this study by the treating physician.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tumor shrinkage rate at the end of protocol treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Lesion disappearance rate at the end of protocol treatment Local recurrence rate 6 months after completion of protocol treatment Adverse event rate (local skin reaction) up to 6 months after completion of protocol treatment | — |
Contacts
Public ContactShusuke Yoshikawa
Shizuoka Cancer Center
Outcome results
None listed